Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

84.66CHF
11:30am EST
Change (% chg)

CHF-1.12 (-1.31%)
Prev Close
CHF85.78
Open
CHF85.54
Day's High
CHF85.78
Day's Low
CHF84.56
Volume
6,712,140
Avg. Vol
4,617,557
52-wk High
CHF92.80
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.14
Market Cap(Mil.): CHF224,800.09
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.80
Yield (%): 3.18

Financials

  NOVN.S Industry Sector
P/E (TTM): 15.54 29.45 30.88
EPS (TTM): 5.67 -- --
ROI: 11.90 14.34 13.80
ROE: 17.75 15.85 15.29

BRIEF-Endocyte Inc Says CFIUS Declaration Review Period With Respect To Novartis Deal Expired On Dec. 14

* ENDOCYTE INC - CFIUS DECLARATION REVIEW PERIOD WITH RESPECT TO NOVARTIS DEAL EXPIRED ON DECEMBER 14, 2018

Dec 17 2018

BRIEF-Novartis Receives European Approval For Self-Administration Of Xolair

* NOVARTIS RECEIVES EUROPEAN COMMISSION APPROVAL FOR SELF-ADMINISTRATION OF XOLAIR® ACROSS ALL INDICATIONS

Dec 13 2018

J&J says its psoriasis drug superior to Novartis treatment in study

Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

Dec 12 2018

UPDATE 2-J&J says its psoriasis drug superior to Novartis treatment in study

Dec 12 Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

Dec 12 2018

BRIEF-Novartis Says Data From Eclipse Trial "Really Doesn't Change" Plans For Cosentyx

* WE BELIEVE DATA FROM ECLIPSE TRIAL, WHICH TESTED NOVARTIS' COSENTYX AGAINST JNJ'S TREMFYA , WILL HAVE LIMITED CLINICAL RELEVANCE - NOVARTIS EXECUTIVE SAYS ON CONF. CALL

Dec 12 2018

J&J says its psoriasis drug superior to Novartis' in study

Dec 12 Johnson & Johnson said on Wednesday its drug Tremfya was more effective than a rival medicine from Novartis AG, and met the main goal of a late-stage study in adults with moderate to severe plaque psoriasis.

Dec 12 2018

Swiss stocks - Factors to watch on Dec. 11

ZURICH/BERLIN, Dec 11 The Swiss blue-chip SMI was seen opening 1.0 percent higher at 8,634 points on Tuesday, according to premarket indications by bank Julius Baer .

Dec 11 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

Dec 06 2018

J&J unit to pay $360 million to U.S. to resolve charity kickback probe

BOSTON A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

Dec 06 2018

UPDATE 3-J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.

Dec 06 2018

Earnings vs. Estimates